Premarket Shockwaves: Replimune, Chevron, Apple, Amazon, and Moderna Lead the Surge

In the premarket session, Replimune, Chevron, Apple, Amazon, and Moderna stocks are delivering dramatic single‑direction moves that dominate trader attention.

Replimune's FDA Approval Anticipation

Replimune (RPLMD) shares jumped %15, pushing its market cap to $12.5M. The biotech is buzzing over rumors that its rare‑disease immunotherapy is on the brink of FDA approval.

■%15 gain marks the biggest daily rise in the past five days.

■Trading volume was 3x the average.

■Analysts target a price of $25.

Energy Giant Chevron's Market Pullback

Chevron (CVX) shares slipped %2.3, settling at a $162.7B market cap as oil prices fell and quarterly earnings missed expectations.

■%2.3 decline underperformed the S&P 500 Energy Index.

■Daily volume hit 1.1M shares, about 120% of the norm.

■CEO Mike Wirth highlighted a cost‑reduction plan.

Apple’s Earnings Outlook and Stock Impact

Apple (AAPL) rose %1.2, reaching a $2.4T market cap after previewing its quarterly earnings. Strong iPhone sales and services growth are fueling optimism.

■%1.2 rise aligns with an estimated EPS of $1.42.

■Services revenue projected to grow %8.

■Analysts recommend a target price of $190.

Amazon’s Guidance Signals

Amazon (AMZN) fell %0.8, holding a $1.36T market cap as FY23 revenue guidance was slightly lowered, sparking concerns over logistics costs and cloud growth.

■%0.8 dip reflects a %3 revision in FY23 revenue outlook.

■AWS revenue growth forecast at %12.

■Stock watches the $3,300 support level.

Moderna’s Vaccine Updates

Moderna (MRNA) surged %6, lifting its market cap to $65B after positive Phase 3 trial results for a next‑gen mRNA vaccine.

■%6 jump driven by a %95 success rate in Phase 3 trials.

■Volume surged to 2.5x the average.

■Analysts set a target price of $180.

The market is closely tracking the catalysts behind these one‑sided moves. Biotech names like Replimune and Moderna remain highly sensitive to FDA and clinical milestones, while macro‑sensitive giants (Chevron, Apple, Amazon) react to broader economic data and guidance revisions. With the VIX hovering around %12, the options market is primed for a potential gamma squeeze, urging investors toward a cautious, balanced positioning.